Articles tagged with Uterine Cancer
The Victoria's Secret Global Fund for Women's Cancers has awarded five female researchers for their groundbreaking work on breast and gynecologic cancers. The recipients will receive a $100,000 honorarium and be invited to participate in a broader women's cancers grant program.
A recent clinical trial has shown that a combination therapy of abemaciclib and letrozole can effectively treat patients with recurrent ER-positive endometrial cancer. The study found that 75% of patients experienced tumor shrinkage or stabilization, making it a promising alternative to current treatments.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
A common mutation in a rare cancer subtype has led researchers to an already-approved drug that shows promise against uterine serous carcinoma. The RNR inhibitor clofarabine effectively stops the highly aggressive type of cancer in its tracks.
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
A nationwide study published in JAMA Oncology found that immunotherapy use among trial-ineligible solid-tumor cancer patients increased significantly between 2014 and 2019, yet no survival benefit was observed. Researchers emphasize cautious use of immunotherapies for this population due to potential early harm.
A collaborative team identified multiple genes with recurrent alterations in uLMS, including HRD, ALT, C-MYC/BET, and PI3K-AKT-mTOR pathway, as potential targets for new treatments.
Researchers at Baylor College of Medicine identified proteomic signatures associated with aggressive cancer types, including altered cellular pathways and novel therapeutic targets. The study provided proof-of-concept that proteomics analysis is a valuable strategy to identify potential therapeutic targets.
A new study reveals that over half of cancer survivors in the US have additional medical conditions linked to severe COVID-19. The findings highlight the importance of protecting cancer survivors from transmission and prioritizing them in vaccine allocation.
L-Grb2 antisense oligodeoxynucleotide (L-Grb2) has promising antitumor activity in preclinical models of ovarian and uterine carcinoma, reducing angiogenesis and increasing apoptosis. L-Grb2's therapeutic efficacy suggests a potential new target for cancer treatment.
Researchers have discovered a gene signature, USC73, that can identify women with rare and aggressive uterine serous carcinoma who are unlikely to respond to standard chemotherapy. The high USC73 score is associated with poor patient survival, cancer cell proliferation, and low rates of complete response to treatment.
A study has identified frequent cancer-driving mutations in healthy human endometrium, suggesting that these events may occur early in life. These mutant stem cells can accumulate further driver mutations over time, leading to invasive cancer years or even decades later.
A study led by Northwestern University found that radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer. Chemotherapy alone remains the standard of care for this type of cancer.
Incidence rates of uterine cancer's aggressive subtypes increased dramatically among all racial groups from 2000 to 2015, with black women having higher rates and poorer survival. Endometrioid subtypes showed stable trends in white women but increasing rates in other groups.
Cancer rates linked to obesity are rising faster in US young adults compared to older generations. Incidence of certain cancer types such as colorectal, uterine corpus, and pancreatic cancer has increased significantly in younger age groups.
A new study finds rates are increasing for six of 12 obesity-related cancers in younger adults in the US, with steeper increases in progressively younger ages. Excess body weight is a known carcinogen associated with more than a dozen cancers and suspected in several more.
Researchers at Baylor College of Medicine have discovered that the TGF-beta signaling pathway acts as a tumor-suppressor mechanism in the uterus, preventing endometrial overgrowth and transformation into cancer cells. This finding suggests potential new treatments for uterine cancer patients.
Researchers at Karolinska Institutet identified four distinct molecular subtypes of undifferentiated uterine sarcoma, a rare and aggressive cancer, which could lead to improved treatment outcomes. The study also showed that some patients may live longer than initially predicted.
A new study found that uterine cancer survivors are more likely to experience cardiovascular problems years after treatment. The researchers identified a significant association between endometrial cancer diagnosis and an increased risk of heart diseases, peripheral and vascular atherosclerosis, and other circulatory disorders.
A recent presentation highlights the need for individualized assessment based on patient characteristics and risk factors to diagnose postmenopausal bleeding. The standard diagnostic approach has changed over the past 25 years, but no single method is suitable for all patients.
Researchers identified 22 genes-of-interest with mutation frequencies across the largest group of CCEC patients. They also uncovered mutations in the TAF1 gene and found similarities to serous endometrial cancer or endometrioid endometrial cancer in a substantial number of CCECs.
Overall cancer death rates have decreased for 11 types of cancer in men and 13 in women between 2010-2014. Five-year survival improved significantly for prostate, kidney, non-Hodgkin lymphoma, and leukemia cancers.
Researchers created a genome-wide map of genes switched on and off in aggressive uterine cancer tumors, revealing a 'signature' of these switches throughout the genome. This discovery supports the idea that cancer cells suffer from an 'identity crisis', switching off specific genes to spread quickly.
Researchers found similar disease-free survival and overall survival outcomes between laparoscopic and abdominal hysterectomies for stage I endometrial cancer. The study suggests the use of laparoscopic hysterectomy as a viable alternative to traditional abdominal surgery.
Researchers analyzed 57 tissue samples from women with uterine carcinosarcoma and found that the tumors share some genetic traits but also exhibit great diversity. This diversity makes it challenging to find effective treatments for the cancer, which has a low survival rate.
A Mayo Clinic study finds that vaginal microbes are distinct in women with endometrial cancer compared to those without the disease. Researchers hope to use vaginal swabs as an early screening tool and investigate the role of the microbiome in preventing endometrial cancer.
Researchers discovered cancer-driving gene mutations in uterine lavage fluid of women with and without endometrial cancer. The study's findings suggest that these pre-cancerous mutations can be detected using advanced genomic technologies, potentially leading to earlier diagnosis and improved treatment outcomes.
A study published in PLOS Medicine found that mutations driving endometrial cancer can be detected in uterine lavage fluid of pre- and post-menopausal women, regardless of their cancer status. The presence of these mutations was positively associated with age and post-menopause, highlighting the potential for non-invasive screening met...
A new study by Penn Medicine found that delaying surgery after a diagnosis of uterine cancer can increase a woman's risk of death, while operating too soon can also be detrimental. The study suggests prioritizing pre-surgical care and specialist referrals over timing.
Researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas, pointing to possible new treatments. The study identified key mutations in cancer genes that may explain the mixed tissue characteristics of these tumors.
The use of electric power morcellation for hysterectomy declined significantly following the FDA's safety communication in April 2014. The prevalence of abnormal pathology remained unchanged despite the decline in morcellation use, highlighting the need for continued caution in patient selection.
A new study published in JAMA Oncology found that women with BRCA1 mutations are at increased risk for developing aggressive serous/serous-like endometrial cancer after undergoing risk-reducing salpingo-oophorectomy (RRSO). The risk is estimated to be 2.6% by age 70.
A study published in JAMA Oncology found that women with the BRCA1 gene mutation have a significantly higher risk of developing serous endometrial cancer, which has a mortality rate of 50%. The study suggests that women with this genetic mutation should consider removing their uterus along with their ovaries and fallopian tubes. Resear...
Researchers have identified five new gene regions associated with an increased risk of developing endometrial cancer, bringing the total number of known risk regions to nine. This discovery doubles the number of genetic risk factors known for the disease, which affects one in four women worldwide.
A new study finds that minimally invasive hysterectomies for early uterine cancer are less accessible to poor and minority women, despite being linked to fewer postoperative complications. The procedures occurred only 23.6% of the time in low-volume hospitals, which performed fewer than 10 hysterectomies annually.
Gynecologists argue the FDA's warning on power-morcellation is based on flawed data and may limit access to safe, effective treatment options for women. The study group suggests that better preoperative identification and new techniques could improve patient outcomes.
A national insurance database analysis revealed that 1 in 352 women had unsuspected cancer after undergoing minimally invasive gynecologic surgeries. The study highlights the need for safer alternatives to power morcellation to avoid worsening a woman's prognosis.
A new study found that laparoscopic hysterectomy without morcellation was the most effective procedure, while laparoscopic hysterectomy with power morcellation was associated with more intraoperative complications but fewer perioperative risks. The risk of cancer dissemination and mortality varied by age, with higher risks for older wo...
A study found that bariatric surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them. It also improved insulin levels and glucose use, altering the composition of gut bacteria.
A study published in JNCI found that women with tubal ligation who develop aggressive endometrial cancer types have lower mortality rates. The researchers suggest that TL reduces cancer cell passage through the fallopian tubes, lowering disease stage and mortality.
Researchers have discovered a new biomarker, ASRGL1, that can identify women with uterine cancer at high risk of recurrence. The study found that patients with low levels of ASRGL1 had a higher risk of recurrence and died from the disease.
A large-scale study found a 0.22% incidence of uterine sarcoma in women after hysterectomy, with most cases being unexpected endometrial cancer. Researchers emphasized the need to balance minimally-invasive procedures with cautious preoperative planning.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that women diagnosed with polycystic ovary syndrome (PCOS) are twice as likely to be hospitalized for reasons unrelated to reproductive health or injury. The study, which examined health records of over 2,500 women with PCOS, also foun...
A recent UTMB study found that Hispanic women in the US were significantly less likely to survive endometrial uterine cancer compared to non-Hispanic white women. The study analyzed data from 69,764 women diagnosed between 2000 and 2010 and found that minority patients tend to be diagnosed with more aggressive cancer.
Scientists at MD Anderson Cancer Center have discovered genetic mutations in a subset of endometrial cancer patients that are associated with a more lethal form of the disease. The identification of these mutations could lead to the development of targeted treatments and improved patient outcomes.
A study published in JAMA examined the prevalence of underlying cancer in women undergoing minimally invasive hysterectomy using morcellation. The researchers found uterine cancers present in 27 per 10,000 women at the time of the procedure, with advanced age associated with underlying cancer and endometrial hyperplasia.
A new study suggests that US cervical cancer incidence rates may be underestimated due to the inclusion of women who have undergone a hysterectomy in calculations. Rates were found to increase with age, particularly among older women and black women.
A retrospective cohort study of 7,431,858 patients found that bariatric surgery significantly reduces the risk of endometrial cancer. Bariatric surgery can lead to normal hormone levels, decreased inflammation, and improved overall health.
A recent study published in BJU International found that radiation therapy used to treat uterine cancer may increase the risk of developing bladder cancer. Patients treated with pelvic radiation therapy had a twice-higher incidence and nearly three times higher death rate from bladder cancer compared to those without radiation.
The study found that epigenetic modification of the HAND2 gene plays a critical role in endometrial cancer development. Hand2 methylation is already increased in premalignant endometrial lesions and predicts a poor response to progesterone treatment.
Researchers at Yale University have defined the genetic landscape of uterine serous carcinoma (USC), a chemo-resistant form of endometrial cancer. The study identifies three previously unknown genes that play a role in tumor growth and development, offering new avenues for personalized therapy.
A new study from Henry Ford Hospital found that delaying radiation therapy after hysterectomy can increase the risk of uterine cancer recurrence. Patients who started treatment within nine weeks after surgery had a five-year relapse-free survival rate of 90%, compared to 43% for those treated later.
Researchers have identified three novel genes - CHD4, FBXW7 and SPOP - that are frequently altered in serous endometrial cancer, a rare and aggressive form of uterine cancer. These findings may lead to new therapeutic targets for this devastating disease.
A large international study found that women who give birth at age 30 or older have a reduced risk of endometrial cancer. The risk decreases by approximately 13 percentage points for each five-year delay in last births, with the greatest reduction seen among women who give birth between ages 35 and 39.
A new study found people with Lynch syndrome have an increased risk of developing several types of cancer, including bowel, uterus, ovarian, kidney, stomach, and bladder cancers. The study also revealed a moderately increased risk of breast and pancreatic cancer in those with the condition.
Experts Roger Short and Kara Britt argue that nuns should be given the contraceptive pill due to its link to reduced ovarian and uterine cancer risk. The pill's overall mortality benefits, particularly in nulliparous women, make it a viable health option for nuns.
Researchers at Henry Ford Hospital found that African American patients are more likely to have a recurrence of uterine cancer after undergoing a total hysterectomy or radiation therapy. The study, which analyzed 750 patients, also identified higher tumor grade and cancer stage as risk factors for recurrence.
Babies born to parents who underwent cancer treatment in childhood or adolescence show minimal risks, according to two new studies. Female cancer survivors had a higher risk of preterm and low birth weight infants compared to the general population, but no increased risk of birth defects or infant death.